Bazan, Hernan A.
Bhattacharjee, Surjyadipta
Reid, Madigan M.
Jun, Bokkyoo
Polk, Connor
Strain, Madeleine
St Pierre, Linsey A.
Desai, Neehar
Daly, Patrick W.
Cucinello-Ragland, Jessica A.
Edwards, Scott
Recio, Javier
Alvarez-Builla, Julio
Cai, James J.
Bazan, Nicolas G.
Funding for this research was provided by:
National Institutes of Health (1R42NS119103-01A1)
Article History
Received: 4 March 2024
Accepted: 9 May 2024
First Online: 15 May 2024
Competing interests
: H.A.B., J.A.-B., and N.G.B. are named on a patent assigned to the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College and University Alcalá de Henares describing the synthesis and characterization of the novel non-hepatotoxic acetaminophen analogs, patent application PCT/US2018/022029, international filing data 12.03.2018; publication date 28.02.2019; which has been nationalized in numerous jurisdictions. H.A.B. and N.G.B. are co-founders of South Rampart Pharma, which has a license and commercial interest in the above patent applications, including a financial interest in the commercial success of SRP-001. They stand to potentially receive financial payments if SRP-001 is commercially successful.